Information Provided By: 
Fly News Breaks for December 13, 2018
ARNA
Dec 13, 2018 | 07:07 EDT
Berenberg analyst Patrick Trucchio initiated Arena Pharmaceuticals with a Buy rating and $55 price target, citing his view that ralinepag still has upside potential and that etrasimod may "emerge a winner in the crowded IBD area." He also believes that olorinab, which is in Phase 2 development for visceral pain associated with IBD and IBS, may eventually be worth as much, or more, than ralinepag, Trucchio tells investors.
News For ARNA From the Last 2 Days
There are no results for your query ARNA
